menu search

Ibio further expands tech stack with shieldtx™; enhances immuno-oncology development pipeline with conditionally activated muc16xcd3 bispecific

– ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action – BRYAN, Texas and ...

November 1, 2023, 12:24 pm

Regeneron to showcase progress from innovative oncology portfolio in several difficult-to-treat cancers at esmo

Event-free survival of investigational use of Libtayo® (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be ...

October 15, 2023, 10:05 pm


Search within

Pages Search Results: